Saturday, 20 April 2024
Thursday, 30 Nov 2023 12:00 am

Bioproduction Market is expected to reach US$ 63,393.93 million in 2030

The global bioproduction market size is estimated to grow from USD 22,337.24 million in 2022 and to reach a value of USD 63,393.93 Million by 2030.

By The Insight Partners

Cancer Segment to Hold Significant Share of Bioproduction Market During 2022–2030  

According to our latest study on "Bioproduction Market Forecast to 2030 – Global Analysis – by Product, Application, Equipment, and End User," the bioproduction market value is expected to reach US$ 63,393.93 million in 2030 from US$ 22,337.24 million in 2022. The report emphasizes the key factors driving the market and prominent players with their developments. The rising adoption of regenerative medicines and increasing prevalence of chronic diseases are the key driving factors behind the market development. However, the high cost of cell therapy and biosimilar manufacturing is hampering the market growth.

The rise in healthcare expenses has coincided with advancements in cancer care. The development of biosimilars has resulted from strategies to reduce the overall cost of oncology drugs and cost-containment techniques are being prioritized in the US and globally. For a number of reasons, biologics are crucial in the treatment of cancer. Biologic medications can help the patient's body recognize and combat cancer cells. Certain biologics directly target cancer cells by interfering with their growth signals. After chemotherapy, various biologics can aid in the battle against infection. In the US, colon, stomach, and breast cancers, among other malignancies, can be treated with FDA-approved biosimilars. They can also be utilized to address adverse effects of cancer therapies, for instance, decreased white blood cell counts that heighten the vulnerability to infections. Biologicals are being used as both therapeutic and supportive care agents in the treatment of cancer. Trastuzumab (Herceptin) is an example of a biological medicine, a targeted cancer drug that is used to treat advanced stomach cancer and breast cancer. The biosimilars for this drug include Herzuma and Ontruzant.

To get free sample copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/brochure/TIPRE00030322

Bioproduction Market, by Product:

The bioproduction market, by product, is segmented into biologics and biosimilars, vaccines, cell and gene therapies, nucleic acid therapeutics, and others. The biologics and biosimilars segment held the largest share of the market in 2022; the cell and gene therapies segment is projected to register the highest CAGR in the market during 2022–2030.

Cell therapy and gene therapy are the overlapping fields in biomedical treatment and research. Both therapies aim to prevent, treat, or potentially cure diseases. Moreover, both therapies have the potential to improve the main cause of genetic and acquired diseases. Cell therapy intends to treat diseases by restoring or modifying several sets of cells outside the body before being injected into the patient or by using cells to carry a therapy across the body. Gene therapy aims to treat diseases by restoring or introducing new genes into cells—either outside of the body (ex vivo) or inside the body (in vivo). The gene therapies work by adjusting genes in specific types of cells and incorporating them into the body.

Bioproduction Market, by Equipment:

The bioproduction market, by equipment, is segmented into consumables and accessories, downstream equipment, bioreactors, and upstream equipment. The consumables and accessories segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during 2022–2030. Bioproduction involves utilizing various consumables and accessories, such as cells, reagents, enzymes, and growth mediums. It also requires disposable glassware and plastic ware such as petri dishes, test tubes, pipettes, automated pipette tips, and beakers. These consumables are used at every step of the cell therapy manufacturing process. They are also required at the time of the quality control (QC) process to ensure appropriate quality testing. Continuous research and developments in the biopharmaceutical industry are likely to demand more consumables and accessories in the coming years. These are also demanded in more quantity as, most of the time, consumables are used for trial-and-error processes.

Bioproduction Market, by End User:

The bioproduction market, by end user, is segmented into biopharmaceutical companies, contract manufacturing organizations, and others. The biopharmaceutical companies segment held the largest market share in 2022. The contract manufacturing organizations segment is anticipated to register the highest CAGR of 14.7% in the market during 2022–2030.

The number of biopharmaceutical companies is increasing worldwide, leading to a high number of collaborations and agreements between the companies. Investments by companies in the research and development of drugs and other biosimilars have been increased. The advancement in biotechnology has improved the identification of possible targets for a drug. During the drug development process, identification and screening targets are important. These targets are identified to meet medicinal chemistry. Also, it is important to optimize those targets to increase affinity. The development of cell-based therapies is at the forefront among various research and development departments of biotechnology companies. The culturing and assay conduction are critical tasks performed by the personnel in these companies that require an appropriately safe and well-equipped workstation.

Bioproduction Market, by Geography:

Based on geography, the bioproduction market is primarily divided into North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc are the prominent bioproduction market players.


Contact Us
Contact Us: The Insight Partners 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

The Insight Partners :    https://www.theinsightpartners.com

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
© The News and Media Division of The Insight Partners 2024 | All Rights Reserved | Privacy Policy